Search Results for "Breast Pap Test Trial"

05:25 EDT 31st July 2015 | BioPortfolio

Matching Channels

Sniff test

Schilling test

Spirometry Test

The gold standard in lung testing In the same way that blood pressure measurements provide a simple yet effective screening method for cardiovascular disease, spirometry tests can help to unmask t...

Breast Lumps

OncoDEEP

At OncoDNA, our philosophy is to provide the most suitable test in terms of rapidity and cost. That’s why we follow a 3 tier approach to find tumour mutations which can respond to new cancer t...

Matching News

The Nottingham Prognostic Index Plus test for breast cancer management

The Nottingham Prognostic Index Plus test (NPI+) is a biomarker-based test developed by the University of Nottingham to support individualised clinical decision making in breast cancer treatment. The ...

CASI Starts China Arm of Phase II Breast Cancer Trial

CASI Pharma, a US biopharma with strong China connections, has begun a China Phase II trial of its lead molecule, ENMD-2076, in triple-negative breast cancer. The trial is a China arm of an on-going P...

Zinc Test Could Help Diagnose Breast Cancer Early

A team, led by Oxford University scientists, took techniques normally used to analyze trace metal isotopes for studying climate change and planetary formation and applied them to how the human body pr...

Income inequality affects who gets an underutilized test for breast cancer

Wealthier women who live in communities with the greatest income divide between rich and poor had better access to a new genetic test that can determine the most effective form of treatment for early-...

Income inequality affects who gets an underutilised test for breast cancer

Wealthier women who live in communities with the greatest income divide between rich and poor had better access to a new genetic test that can determine the most effective form of treatment for early-...

Genetic test analyses 77 genes for breast cancer risk

A new wide-ranging test that looks at multiple sites in the DNA code could help predict a woman's risk of developing breast cancer...

CMS drafts coverage of NanoString's breast cancer test

A positive local coverage determination draft was released by the CMS for the Prosigna breast cancer recurrence test develope -More- 

Breast cancer Dx test from BioNTech debuts in EU

The MammaTyper diagnostic test for breast cancer has been released by German medtech firm BioNTech in the European market.  -More- 

Matching PubMed Articles

The genomic expression test EndoPredict is a prognostic tool for identifying risk of local recurrence in postmenopausal endocrine receptor-positive, her2neu-negative breast cancer patients randomised within the prospective ABCSG 8 trial.

The aim of this study was to examine whether EndoPredict (EP), a novel genomic expression test, is effective in predicting local recurrence (LR)-free survival (LRFS) following surgery for breast cance...

Evidence for biological effects of metformin in operable breast cancer: biomarker analysis in a pre-operative window of opportunity randomized trial.

Metformin has therapeutic potential against breast cancer, but the mechanisms of action in vivo remain uncertain. This study examined biomarker effects of metformin in primary breast cancer in a preop...

Minimal impact of adjuvant exemestane or tamoxifen treatment on mammographic breast density in postmenopausal breast cancer patients: A Dutch TEAM trial analysis.

Background. Mammographic breast density is one of the strongest independent risk factors for developing breast cancer. We examined the effect of exemestane and tamoxifen on breast density in Dutch pos...

Text-message reminders increase uptake of routine breast screening appointments: a randomised controlled trial in a hard-to-reach population.

Background:There is a need for interventions to promote uptake of breast screening throughout Europe.Methods:We performed a single-blind randomised controlled trial to test whether text-message remind...

Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial.

For most older women with early breast cancer, standard treatment after breast-conserving surgery is adjuvant whole-breast radiotherapy and adjuvant endocrine treatment. We aimed to assess the effect ...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement